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It was shown severalyearsago by Hellstrom et al . (1) that sublethal x irradiation
of mice bearing palpable syngeneic tumors can result in partial or complete
tumor regression . These same authors showed, in addition, that the therapeutic
effect of irradiation depended on the tumors being above a certain size, and that
regression failed to occur if the mice were infused, immediately after irradiation,
with T cells from normal donor mice . It was logical to suggest, therefore, that
irradiation-induced tumor regression is immunologically mediated, and that it
depends on the ability ofx irradiation to selectively eliminate suppressorT cells
(1). Considering that this is one of the few convincing examples of successful
immunotherapy of established tumors, I considered it important to investigate it
in more detail with the tumors under study in this laboratory . There remained
a need, for example, to provide causal evidence that irradiation-induced tumor
regression is immunologically mediated, and to document that it is associated
with increased production of effector T cells on the one hand, and with the
absence of suppressorT cell production on the other .
Assays that can measure the tumor-induced production of effector and sup-
pressor T cells have been developed in this laboratory as a result ofan investi-
gation (2, 3) of the generation and decay of concomitant immunity to several
immunogenic tumors . It was revealed (4, 5) with the tumors under study in this
laboratory that between days 6 and 9 oftumor growth, the tumor-bearing host
generates tumor-sensitized T cells that can, on passive transfer, cause regression
ofa small tumor in irradiated recipients . After day 9, however, these effectorT
cells are progressively lost, and this is temporally associated with the progressive
acquisition of T cells that can, on passive transfer, suppress the expression of
adoptive immunity against an established tumor in test recipients . Therefore,
during progressive tumor growth, the abridgement of effector T cell production
is associated with the onset of suppressor T cell production . It was hypothesized,
therefore, that immunogenic tumors grow progressively, in spite of their posses-
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sion of transplantation rejection antigens, because the immune response they
evoke in their immunocompetent hosts is downregulated by suppressor T cells
before enough effector T cells are produced to cause tumor regression (4, 5) .
The purpose of this paper is to show that whole-body y irradiation can cause
complete regression of immunogenic tumors growing in immunocompetent, but
not in immunoincompetent mice, and that regression can be inhibited by infusion
of L3T4+ suppressor T cells from tumor-bearing donors. It will show, in addition,
that tumor regression is associated with a sustained production of effector T
cells, and with a failure to produce suppressor T cells.
Materials and Methods
Mice. BALB/c, DBA/2, A/Tru, CB6 (BALB/c X C57BL/6), B6D/2 (C57BL/6 X
DBA/2), and AB6 (A/Tru X C57BL/6) adult mice (10-12 wk of age) were obtained from
the Trudeau Institute Animal Breeding Facility. The mice were reared under barrier-
sustained conditions, and were shown to be free of common viral pathogens according to
tests routinely performed by the Diagnostic Testing Service of Microbiological Associates,
Bethesda, MD.
Tumors.
￿
The Meth A fibrosarcoma (BALB/c), P815 mastocytoma (DBA/2), L5178Y
lymphoma (DBA/2), P388 lymphoma (DBA/2), and SA1 sarcoma (A/J) were passaged as
ascites, harvested, cryopreserved, and prepared for implantation as described previously
(4, 6). The origins of these tumors have also been described in previous publications (4-
6). For experiments, tumors were initiated intradermally in the belly region of semisyn-
geneic hosts by injection of 106 tumor cells in a volume of 0.05 ml of PBS. Tumor growth
and regression were monitored by measuring changes against time in the mean of two
diameters measured at right angles.
Irradiation.
￿
Mice were irradiated in a' s'Cs irradiator (Atomic Energy of Canada Ltd.,
Ottawa) that delivered a midphantom dose rate of 30 rad/min.
Assayfor Suppressor T Cells.
￿
The presence of suppressor T cellsin the spleens oftumor
bearers was determined by measuring the capacity of spleen cells to suppress, on intrave-
nous infusion, the ability of passively transferred immune spleen cellsfrom tumor-immune
donors to cause regression of a 4-d intradermal tumor in T cell-deficient test recipients,
as described in previous publications (4, 5). Recipient test mice were made T cell deficient
(TXB)' by thymectomy at 6 wk ofage, followed 1 wk later by lethal (900 rad) 'r irradiation.
Immediately after irradiation they were infused intravenously with 10' syngeneic bone
marrow cells and they were used after an additional 4 wk. Donors of immune spleen cells
were mice that had been immunized several weeks earlier by intradermal injection of an
admixture of 1-2 X 106 living tumor cellsand 100 lAg ofPropionibacterium acnes (formalin-
killed Corynebacterium parvum from Burroughs Wellcome Co., Research Triangle Park,
NC). At the time of harvesting their spleen cells, the donors possessed a state of
immunological memory (7). Their spleens were diced into small pieces and pushed through
a 60-mesh stainless screen into PBS. The resulting cell suspension was triturated to break
up clumps, passed through sterile surgical gauze to remove debris, washed twice in PBS,
and was resuspended in PBS for intravenous infusion.
Suppressor donors were mice bearing one or another of the tumors under study.
Suspensions of donor spleen cells were obtained by the method used for obtaining
suspensions of immune T cells. The suppressor assay involved infusing TXB recipients
bearing a 4-d intradermal tumor intravenously with one spleen equivalent (-1 .5 X 108)
of immune spleen cells, followed 1 h later by infusion of one spleen equivalent (1 .5-2 .0
X 108) of suppressor T cells from donors bearing an established tumor. With this assay,
the level of suppression transferred is indicated by the degree to which immunologically
mediated regression of the recipient tumor is inhibited (4, 5).
Assay for Effector T Cells.
￿
The assay for measuring the production of effector T cells
' Abbreviation used in this paper:
￿
TXB, T cell-deficient.
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Evidence that 500 rad ofwhole-body ti irradiation of mice bearing a day 6 tumor
(arrow) caused complete tumor regression, aftera 3-4 d delay. The same result was obtained
with the Meth A fibrosarcoma, SA1 sarcoma, and L5178Y lymphoma, each growing from an
intradermal implant. Means of five mice per group.
in mice bearing a progressive tumor has been described previously (4, 5). It involved
determining the capacity of one organ equivalent of splenic T cells from tumor bearers
to cause, on passive transfer, regression of a 3-d tumor in recipients that were exposed to
500 rad of y radiation 1 h before receiving spleen cells. The method for obtaining spleen
cells was the same as described above.
Deleting TCell Subsets.
￿
T cell subsets were deleted by treating spleen cells with culture
medium in which hybridomas (5 x 105 cells/ml) secreting anti-Ly-1 .2 antibody (clone
CP30 from Dr. Jan Klein, Max Plank Institute, Tubingen, Federal Republic of Germany),
anti-Ly-2.2 antibody (clone TIB-150 from the American Type Culture Collection, Rock-
ville, MD), or anti-L3T4 antibody (clone GK-1 .5 from Dr. Frank Fitch, Department of
Pathology, University of Chicago, IL)) had been growing. The spleen cells were treated
at 2 x 10' cells/ml for 30 min at 4°C in the appropriate antibody-containing culture
medium, and then with the same volume of a 1 :10 dilution of rabbit serum as a source of
complement, as previously described (4, 5).
y Irradiation Resulted in Regression of Three of Fine Tumors Tested.
￿
It was
necessary first to confirm the findings of others (1) that whole-body irradiation
can cause partial or complete regression of immunogenic tumors. It can be seen
in Fig. 1 that 500 rad of 7 radiation given on day 6 of tumor growth caused
complete regression of the Meth A fibrosarcoma, SA-1 sarcoma, and L51 78Y
lymphoma, with the onset of regression occurring after a delay of several days.
In contrast, Fig. 2 shows that the same dose of -y radiation had only a marginal
therapeutic effect against a 6-d P815 mastocytoma, and no therapeutic effect at
all against a 6-d P388 lymphoma. Since all of the tumors tested are known to be
immunogenic (capable of immunizing against growth of a subsequent implant),
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FIGURE 2.
￿
Evidence that 500rad of whole-body y irradiation (arrow) didnotcauseregression
of the less immunogenic P815 mastocytoma, or P388 lymphoma. Means of five mice per
group. ", irradiated; O, control.
it is apparent that these latter two tumors are less immunogenic than the others,
assuming that irradiation-induced regression is immunologically mediated .
Evidence that Irradiation-induced Tumor Regression Is Immunologically Medi-
ated.
￿
If irradiation-induced tumor regression is immunologically mediated, it
would follow that whole-body irradiation should have no effect against a tumor
growing in mice that have been rendered incapable of generating an antitumor
immune response. This prediction was tested by determining whether 500 rad
of y irradiation would cause regression of a 6-d Meth A fibrosarcoma growing
in TXB mice. Fig. 3 clearly shows that, whereas y irradiation caused complete
regression of the Meth A tumor growing in immunocompetent mice, it had no
therapeutic effect at all against the same sized tumor growing in TXB mice.
Therefore, irradiation-induced tumor regression depends on an intact T cell
system.
Irradiation-induced Regression Is Blocked by Infusion ofL3T4' TCellsfrom Tumor-
bearing Donors. According to the results of others (1), the therapeutic effect of
irradiation can be blocked by infusing the tumor-bearing host, immediately after
irradiation, with T cells from normal mice. However, attempts in this laboratory
to confirm this result with the Meth A fibrosarcoma were unsuccessful, in that
infusion of as many as three spleen equivalents of normal T cells failed to
interfere with the therapeutic effect of irradiation. On the other hand, it proved
easy to show in a routine fashion that the therapeutic effect of irradiation against
the Meth A tumor could be blocked by infusing the host with spleen cells from
donor mice bearing an established Meth A tumor. It can be seen in Fig. 4 that,
whereas infusion of 3 x 108 spleen cells from normal donor mice failed to inhibit
regression of an established Meth A tumor in 7-irradiated recipients, 1.5 x 108
spleen cells from donors bearing a 6-d or a 16-d Meth A tumor inhibited tumor
regression in all mice. It needs to be pointed out, moreover, that the results of1656 TUMOR REGRESSION BY THERAPEUTIC IMMUNOMANIPULATION
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￿
The therapeutic effect of 500rad of y irradiation was Tcell dependent. Whereas
irradiation causes complete regression of the Meth A fibrosarcoma growing in immunocom-
petent mice (left panel), it had no effect on the same-sized tumor growing in TXB mice (right
panel). Means offive mice per group. Irrad, irradiation.
FIGURE 4.
￿
y irradiation-induced regression of the Meth A fibrosarcoma was inhibited by
infusing the tumor bearer, immediately after irradiation on day 6 (arrow), with one organ
equivalent (1.5 x 108) of spleen cells from donors bearing a day 6 or day 16 tumor, but not
by three organ equivalents (3 x 108) of spleen cells from normal donors. Means of five mice
per group. ",day 6 spleen ; A, day 16 spleen; O, normal spleen.NORTH
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Evidence that the spleen cells from donors with day 16 tumors that, on passive
transfer, inhibit irradiation-induced regression of a day 6 tumors were Ly-1',2-,L3T4+ T
cells. Their suppressor function was abolished by treatment with anti-Ly-1 .2 antibody and
complement, or with anti-L3T4 antibody and complement, but not by treatment with anti-
Ly-2.2 antibody and complement. Means of five mice per group. X, tumor control; ¢, 500
rad; O, 500 rad + suppressor; 0, 500 rad + suppressor anti-Ly-1, 0, 500 rad + suppressor
anti-L3T4a; E, 500 rad + suppressor anti-Ly-2.
two additional studies (not shown) revealed that spleen cells from 16-d tumor
bearers were more reliable in blocking the therapeutic effect ofirradiation than
spleen cells from donors bearing a day 6 tumor, in that in these additional
experiments only the spleen cells from day 16 tumor bearers inhibited tumor
regression in all recipients. This perhaps is not surprising, given that tumor-
induced suppressor T cells of the type under study in this laboratory can be
detected in increasing number after about day 9 of tumor growth (4, 5). These
tumor-induced suppressor cells have been shown to be Ly-1+,2-,L3T4+ T cells
that can, on passive transfer, suppress the expression of adoptive immunity
against an established tumor in TXB test recipients (4-5).
Evidence that T cells with the same surface phenotype were responsible for
inhibiting irradiation-induced regression ofthe Meth A fibrosarcoma is provided
by the results in Fig. 5. It can be seen that the ability of spleen cells from donors
with a day 16 tumor to inhibit irradiation-induced regression of a 6-d Meth A
tumor was abolished by treating the spleen cells with anti-Ly-1 antibody and
complement, or anti-L3T4 antibody and complement. In contrast, treatment
with anti-Ly-2 antibody and complement was without effect. These results
indicate that y irradiation causes regression by eliminating, or preventing the
production of, Ly-1+,2-,L3T4+ suppressor T cells.
Irradiation-induced Tumor Regression Is Associated with Sustained Production of
T Cell Effectors of Concomitant Immunity. It has been shown with the Meth A
fibrosarcoma (4) and certain other tumors (3) that, in spite of their progressive
growth, they nevertheless evoke in their hosts the generation of an underlying
mechanism of concomitant immunity that is mediated by Ly-2+ T cells. It has1658 TUMOR REGRESSION BY THERAPEUTIC IMMUNOMANIPULATION
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￿
Irradiation-induced regression of the Meth A fibrosarcoma was associated with
sustained production of lymphocytes that could passively transfer immunity. Shown is the
growth of a test tumor in recipient mice that were infused (arrow) with one organ equivalent
of spleen cells harvested from control (left), or irradiated donors (right) 3, 5, 9, 12, 15, or IS
d (numbers on graphs) after the donor tumor began growing. Radiation was given on day 5.
It can be seen that it was possible to cause regression of the recipient tumor with one organ-
equivalent of spleen cells from irradiated donors harvested at any time from day 6 until day
18 when the experiment was terminated. In contrast, tumor-bearing control donors rapidly
lost protective lymphocytes after day9. Thus,regression of the tumorafterday9 in irradiated
mice (see Fig. 7) was associated with the sustained production of immune T cells. Means of
five mice per group.
also been shown (4) that concomitant immunity is generated progressively
between days 6 and 9 of tumor growth, but that it then undergoes progressive
decay in concert with the progressive production ofLy-1+,2- suppressor Tcells.
On the basis of this knowledge it was possible to suggest that irradiation-induced
tumor regression is caused by theability ofirradiation topreferentially eliminate
suppressor T cells, therebyallowingthe production ofeffector Tcells to continue
beyond day 9 of tumor growth . This would allow enough effector T cells to
accumulate to cause tumor regression.
To determine whether y irradiation causes a sustained production of effector
T cells, tumor-bearing mice given 500 rad of y radiation on day 5 of tumor
growth were compared with control tumor bearers at progressive times in terms
of the ability of one organ equivalent of their spleen cells to passively transfer
immunity to recipients bearing a 3-d tumor. In this assay it was necessary to give
the recipient mice 500 rad ofy radiation immediately before passive transfer, to
enable donor spleen cells to express their antitumor function (4, 5).
It was found (Fig. 6) that progressive growth of the Meth A tumor in control
mice resulted in the production ofsplenic Tcells that could, on passive transfer,
cause regression ofa small Meth Atumor in irradiated recipients. Production of
these T cells occurred between days 6 and 9 oftumor growth, after which they
were rapidly lost. It was only on day 9 that the spleens ofcontrol mice contained
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Results in Fig. 6 converted to changes against time in an index of immunity in
tumor-bearing control donors (left) and tumor-bearing irradiated donors (right). The index of
immunity was calculated by subtracting the size of the tumor growing in recipients that
received donor spleen cells, from its size in control recipients on day 22 of the experiment.
An index of 100 means that donorspleen cellscaused complete tumorregression. This figure
shows clearly that irradiated donors whose tumors underwent regression starting on day 9
retained lymphocytes that could cause regression of the recipient tumor untilat least day 18.
enough sensitized T cells to cause complete regression of the recipient tumor.
In contrast, donor mice that received irradiation on day 5 of tumor growth
continued to generate effector T cells well beyond day 9. Indeed the spleens of
irradiated tumor bearers contained effector T cells in numbers large enough to
cause complete regression of the recipient test tumor until day 18, when the
experiment was terminated. This was the case even though irradiation caused a
severe reduction in the total number of spleen cells between days 5 and 18 of
tumor growth .
Indeed, the cellularity ofthe spleens ofmice irradiated on day 5 dropped from
1.5 X 108 to 1.7 X 10' on day 6, and increased progressively thereafter to reach
8 X 10' on day 18. In contrast, the cellularity of control spleens increased from
1.5 X 108 to 2.5 X 108 during the same time period . The sustained presence of
effector T cells in irradiated mice was associated, after day 9, with progressive
regression of the donor tumor. This is shown in Fig. 7, which also plots the
above results in terms of changes in an index of concomitant immunity. Fig. 7
illustrates more clearly the consequences of irradiation on effector T cell pro-
duction.
Irradiation-induced Tumor Regression Is Associated with Failure to Generate Sup-1660 TUMOR REGRESSION BY THERAPEUTIC IMMUNOMANIPULATION
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￿
Irradiation-induced regression of the Meth A ftbrosarcoma was associated with
failure by the host to generate suppressor T cells. Shown is growth of a test tumor in TXB
recipients that were infused (arrow) with the immune spleen cells alone, or immune spleen
cells plus spleen cells from control (left), or irradiated tumor-bearing donors (right)harvested
on day6, 9, 12, 15, or 18 after implanting the donor tumor (numbers on individual graphs).
Tumor regression caused by infusing immune cells alone (IMM CONT, M) was suppressed by
infusing spleen cells from control donors bearinga 12-, 15-, or 18-d tumor, with the degree
of suppression increasing with size ofthe donortumor. In contrast, spleen cellsfrom irradiated
tumorbearers (irradiated on day 5) failed to inhibit tumor regression, regardless of the time
they were harvested. The tumor in the irradiated donors underwent regression starting on
day 9 (see Fig. 9). Means of five mice per group.
pressor T Cells.
￿
It was shown in a preceding section that irradiation-induced
regression of the Meth A ftbrosarcoma can be inhibited by passive transfer of
Ly-1+,2-,L3T4+ T cells from donors bearing an established Meth A tumor. In
other words, regression can be inhibited by T cells with the same surface
phenotype as T cells which, on passive transfer, can suppress the expression of
adoptive immunity, and which are generated progressively after day 9 of tumor
growth (4, 5). It was anticipated, therefore, that irradiation-induced regression
of the Meth A tumor would be associated with a failure on the part of the host
to generate these suppressor T cells. This was investigated by measuring, at
progressive times of tumor growth, the capacity of one organ equivalent of
spleen cells from control or irradiated mice to suppress, on passive transfer, the
ability ofone organ equivalent of passively transferred immune Tcells to cause
the regression of an established tumor in TXB test recipients, according to the
standard suppressor assay (4, 5).
It can be seen in Fig. 8, in agreement with previous findings (4, 5), that control
tumor bearers eventually generatedsplenic T cellsthat could, on passivetransfer,
suppress the ability of spleen cells from immunized mice to cause regression of a
tumor in TXB test recipients . On a per spleen basis, these suppressor cells were
generated progressively after day 9 of tumor growth. In contrast, the spleen of3
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Results in Fig. 8 converted to changes against time in asuppressor index that was
obtained by subtracting growth of the tumor in recipient of immune cells alone from its
growth in recipients of immune cells plus suppressor cellson day 23 of the experiment. This
figure clearlyshowsthat, whereasnormal tumorbearers acquired suppressor cellsprogressively
from day 12 of tumor growth on, irradiated tumor bearers failed to acquire suppressor cells
during the time course of the experiment.
tumor bearers irradiated on day 5 of tumor growth failed to acquire cells that
could passively transfer suppression to adoptively immunized recipients . As
shown in Fig. 9, the tumors in irradiated mice all began undergoing regression
after days 9-12 of growth. Fig. 9 plots suppression in terms of changes against
time in an index of suppression. It illustrates the difference in suppressor
production between control and irradiated mice.
Early Irradiation Causes Enhancement of Tumor Growth.
￿
The foregoing results
leave little doubt that irradiation-induced regression ofthe Meth A fibrosarcoma
is immunologically mediated. They show that irradiation has no therapeutic
effect against a tumor growing in a TXB host, and that regression can be
prevented by infusion, after irradiation, ofTcells from a tumor-bearing donor.
Additional evidence that the dose of radiation used had no direct effect on
growth of the tumor is shown by the results of experiments that determined the
consequences of giving irradiation at different stages of tumor growth. Figs. 10
and I 1 illustrate, with the Meth A fibrosarcoma and SAI sarcoma, respectively,
that whole-body exposure to 500 rad ofradiation shortly after implanting tumor
cells resulted in enhancement ofgrowth ofthe tumors that emerged. In contrast,
exposure to the same dose of irradiation after the tumors had become palpable1662 TUMOR REGRESSION BY THERAPEUTIC IMMUNOMANIPULATION
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FIGURE 10.
￿
Therapeutic effect of 500 rad of y radiation given at different days (numbers
on individual graphs) of growth of the Meth A fibrosarcoma. In this experiment, radiation
wasmost therapeutic when given on day 6, with therapeutic effectiveness fallingoffon either
side of day 6. Note, however, that when radiation was given several hours after implanting
tumor cells (time 0) it caused enhancement of tumorgrowth. Means of five mice per group.
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￿
Same as Fig. 9 except with SAI sarcoma. With this tumor, irradiation caused
complete regression when given on days 4, 6, or 9 of tumor growth (numbers on individual
graphs). This figure better illustrates that irradiating too early (during the first 2 d) after
tumorimplantation caused enhancement of tumor growth. Means of five mice per group.
resulted in complete tumor regression . Thus, the ability of a host to respond
immunologically to its immunogenic tumor changes from being highly radiosen-
sitive to being highly radiostimulative during the first 4 d or so of tumor growth.
It can be seen, moreover, that the therapeutic effect of irradiation decreasedNORTH
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progressively after day 6 oftumor growth, and that the SA1 sarcoma was more
responsive overall to irradiation than the Meth A.
Discussion
The results reported here serve to confirm results published by other authors
(1) showing that exposure of mice bearing a palpable immunogenic tumor to a
sublethal dose of ionizing radiation can cause the tumor to undergo partial or
complete regression, depending on its immunogenicity. However, in disagree-
ment with a key finding by the same authors, this study failed to find evidence
that T cells from normal donor mice can inhibit the therapeutic effect of
irradiation. On the contrary, to inhibit irradiation-induced regression of the
Meth A fibrosarcoma, it was necessary to infuse the irradiated host with T cells
from donors bearing a progressive Meth A tumor. Be this as it may, the results
reported here and by others (1) support the interpretation that the therapeutic
effect ofirradiation isin some way dependenton the elimination ofradiosensitive
suppressor T cells, or their precursors. Any suggestion that irradiation-induced
tumor regression is the result of the direct destructive action of radiation on
tumor cells can be discontinued on the basis of the additional finding that
irradiation failed to cause the regression of tumors growing in TXB mice that
could not generate an antitumor immune response. Therefore, irradiation-
induced regression ofan established tumor is a convincing example of successful
immunotherapy.
A major contributor of the present study to an understanding of this immu-
notherapy is that it provides direct evidence that irradiation-induced regression
is associated with failure of the host to generate suppressor T cells on the one
hand, and with a sustained production of effector T cells on the other. In this
connection, preceding studies from this laboratory have shown (discussed in
references 2 and 3) that, because progressive growth of immunogenic tumors
can evoke the generation of an underlying state of concomitant immunity, the
therapeutic action ofany given agent against an established tumor needs to be
interpreted in terms of the influence of the agent on this underlying immune
response. It is known that the response results in the progressive generation,
between days 6 and 9 oftumor growth, ofLy-2+ T cells that, on passive transfer,
can cause regression of a small 3-d tumor in irradiated recipients (4, 5). After
about day 9, these protective Tcells are progressively lost and this is temporally
associated with the progressive acquisition of Ly-1+,2- suppressor T cells. The
suppressor function of these suppressor T cells is measured in terms of their
capacity to suppress, on passive transfer, the ability of passively transferred T
cells from immunized donors to cause the regression ofan established tumor in
TXB test recipients (4, 5). It was hypothesized, on the basis of these and other
published results (4, 5), that immunogenic tumors grow progressively because
the immune response they evoke in their immunocompetent hosts is down-
regulated by suppressor T cells before enough effector Tcells are generated to
cause tumor regression. The results presented here are entirely consistent with
this hypothesis. They provide convincing evidence that if suppressor T cells are
removed, a large enough number ofeffector T cells can be generated to cause
tumor regression. Thus, failure to generate suppressor T cells after 500 rad of1664 TUMOR REGRESSION BY THERAPEUTIC IMMUNOMANIPULATION
whole-body irradiation results in a sustained production of effector T cells that
can, on passive transfer, cause regression ofatest tumorin appropriaterecipients.
It is interesting in this regard that exposure to radiation on day 6 of tumor
growth does not result in the onset oftumor regression until after about day 9,
when concomitant immunity to the Meth A fibrosarcoma normally begins to
undergo progressive decay. This indicates that tumor regression depends on the
uninterrupted production of effector T cells beyond day 9, rather than on an
accelerated production ofeffector T cells immediately after irradiation. In other
words, a given amount of time is required for therapeutic numbers of effector
T cells to accumulate, even in the absence of suppressor Tcells.
In the case of those tumors that fail to undergo regression in response to
whole-body irradiation, it is apparent that they are not immunogenic enough to
cause the generation of a therapeutic number of effector T cells, even in the
absence ofsuppression. If this proves to be true, it would mean that the negative
regulatory influence of tumor-induced suppressor T cells need not explain the
escape of all immunogenic tumors from immunity. This possibility is currently
under study in this laboratory with the P815 mastocytoma and P388 lymphoma .
Regardless of the reason why some tumors fail to undergo regression in
response to irradiation, there remains the central problem of explaining, in the
case of those that do, why irradiation eliminates suppressor T cells without
effecting the production and function of effector T cells. Obviously effector T
cells are not destroyed, otherwise irradiation would have no therapeutic effect
on the tumor. The problem, then, is not to explain the sensitivity of suppressor
T cells or their precursors to the dose of radiation used, because it is well
documented (reviewed in 8) that suppressor T cells in general are more radi-
osensitive than other lymphocytes, and it is known (6) that the suppressor T cells
generated in response to growth ofthe Meth A fibrosarcoma and other tumors
under study in this laboratory are destroyed in vivo by 500 rad of 7 radiation.
Rather, the problem is to explain why effector T cell production is not abolished
by the same dose of radiation. To this end, it is possible to draw on published
evidence (9) showing that, in contrast to resting lymphocytes that are highly
radiosensitive, B lymphocytes and T lymphocytes thatare activated by mitogens,
or T lymphocytes that are activated by alloantigens, are relatively radioresistant,
in that they survive and function for some time, even after exposure to 1,000
rad ofx radiation. Indeed, it hasbeen shown (9) that continuous lines ofcytolytic
and Th cells can proliferate to a surprising extent after exposure to high doses
ofx rays. This evidence is relevant to the demonstration here (Figs. 10 and 11)
that, whereas irradiation during the first day or so after implanting tumor cells
is highly immunosuppressive, in that it causes enhanced growth of the tumor
that emerges, irradiation 3-5 d later is highly immunoaugmentive in that it
causes immunologically-mediated tumor regression . It is suggested that this
conversion from being radiosensitive to radioaugmentable signifies the onset of
induction ofthe antitumor immune response and the consequential activation of
specifically sensitized T cells to a radioresistant cycling state. Unlike most other
mammalian cells that are radioresistant in a restingstate, and radiosensitive while
cycling, it is apparent that lymphocytes are radiosensitive when resting and
radioresistant while cycling. Obviously, because this does not apply to tumor-induced suppressor lymphocytes, theremust be physiological differencesbetween
activated effector T cells and activated suppressor T cells. There is a need to
discover more acceptable immunotherapeutic modalities to take advantage of
these physiological differences.
Summary
The results of this study confirm results published by others (1) by showing
that sublethal whole-body irradiation of mice bearing immunogenic tumors can
result in complete tumor regression. The results show, in addition, that irradia-
tion-induced tumor regression can be prevented by infusion, after irradiation,
of Ly-1 +,2-,L3T4+ suppressor T cells from the spleens of donors bearing an
established tumor, but not by infusion of normal spleen cells. This evidence, plus
the demonstration that irradiation fails to cause regression of tumors growing in
immunocompetent mice, is consistent with the hypothesis that irradiation-in-
duced regression is immunologically mediated, and that it depends on the ability
of irradiation to preferentially eliminate suppressor T cells. By using passive
transfer assays to measure the production of effector T cells and suppressor T
cells against time of tumor growth, it was shown that irradiation of tumor-bearing
mice on day 5 of tumor growth resulted in a failure to generate suppressor T
cells on the one hand, and in a sustained production, effector T cells on the
other. In other words, irradiation prevented the concomitant antitumor immune
response from being downregulated by suppressor T cells. However, giving
radiation on day 1 of tumor growth, in contrast to giving it 3-6 d later, caused
immunodepression and enhancement of tumor growth . This is in keeping with
published evidence showing (9) that, whereas resting effector T cells are highly
radiosensitive, antigen-activated effector T cells are relatively radioresistant. It
is suggested that the radioresistance of activated effector T cells, coupled with
the radiosensitivity of activated suppressor T cells, is the reason for the selectivity
of ionizing radiation for suppressor T cells and whya tumor needs to be palpable
to undergo regression in response to radiation therapy.
Receivedfor publication 26 June 1986.
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